Human Immunodeficiency Virus Infection Clinical Trial
Official title:
The Effect of an Enhanced Rice Bran Nutritional Supplement on Metabolic Syndrome Variables in HIV
The purpose of this study is to investigate the effects of the nutritional supplement rice bran arabinoxylan compound (RBAC) on metabolic syndrome variables in persons living with HIV. The hypothesis is that there will be a significant improvement in metabolic syndrome and immune variables in HIV-positive participants in the intervention group compared to the control group.
The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound
(RBAC) on metabolic syndrome variables in persons living with HIV (PLWH). This nutritional
supplement is made from a water soluble extract of rice bran that has been partially
hydrolyzed by the action of a natural enzyme complex extracted from Shiitake mushroom. Given
that these micronutrients may be important for regulating the immune system and metabolizing
glucose, the investigators will explore the impact of RBAC on metabolic syndrome (MetSyn)
variables according to the National Cholesterol Education Program (NCEP) Adult Treatment
Panel III guidelines (1) (fasting plasma glucose, waist circumference, high-density
lipoprotein [HDL] cholesterol, triglycerides, and blood pressure), secondarily on additional
atherogenic variables (total cholesterol, low-density lipoprotein [LDL] cholesterol, hip
circumference, and body mass index) and immune functioning (CD4+ and CD8+) among 40 HIV+
adult (18+ years of age and over) patients on stable antiretroviral therapy (ART).
Specifically, subjects will participate in a 6-month, two-group, randomized intervention,
where one group (n=20) will take 3 gram/day RBAC and the other group (n=20) will take a
placebo to compare differences in outcomes between the two groups. The results of the study
are intended to address the multi-faceted physiological problems of HIV+ patients by testing
the efficacy of a nutritional supplement intervention on multiple outcomes in this
population.
No substantial psychological, medical, or social risks exist to the participants, other than
minor discomfort associated with the venipuncture. Although all measures to protect
confidentiality will be put in place, the possibility exists that electronic data could be
jeopardized. In the remote case that such event occurs, it will be immediately reported to
the Institutional Review Board.
The components of RBAC should be harmless without significant food allergies. No serious,
untoward side effects have been reported to the company by consumers nor observed during
previous human studies. Potential adverse effects will be explained to each participant when
informed consent is obtained. Whole foods supplements are virtually no different than
consuming food, because of how they are manufactured. The investigators prior study on RBAC
showed no adverse effects. If any side effect does occur, the remedy is to discontinue until
asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2
days, if uneventful, until full dosage is achieved. Study staff will provide additional
follow-up and consultation with any subject who experiences an untoward side effect.
Other potential risks include:
1. Randomization. A potential risk for the placebo group is no improvement in the
investigators outcomes of interest.
2. Data collection. The investigators foresee minimal risks associated with the testing,
other than discomfort or fatigue.
A toxicology search for each component reveals no unique toxicity characteristic of the
materials. As reported by Daiwa Health Development, the manufacturer of the product,
thousands of people currently use RBAC (under the trade names BRM4 and PeakImmune 4), and
Daiwa is unaware of significant toxicities. Daiwa applies the latest scientific methods to
ensure the value and safety of their raw materials. Daiwa products are manufactured in
state-of-the-art facilities, under strict quality control and environmental protection
standards.
Participants will incur no additional appreciable psychological or social risks by
participating in this study, although they may undergo psychological and physical discomfort
sometimes. The process of interviewing during the assessment may cause discomfort.
Discomfort or fatigue may also be experienced in completing the assessment battery.
Alternatives to this study for these MetSyn and immune functioning variables include
prescription medications, exercise, dietary modification, and other nutritional supplements.
The risks of medications can be very significant, including life-threatening, but the risk
of taking nutritional supplements is not totally understood, since they are not regulated by
the US Food and Drug Administration. Medications and nutritional supplements, as part of a
change in lifestyle behaviors, may also prove to be beneficial for MetSyn variables and
immune system functioning, but their long-term use has unknown consequences.
The information obtained in this study will help in determining the efficacy of using RBAC
on MetSyn and metabolic variables and immune system functioning. By participating in the
study, subjects may experience improved health status. The risk of participating in this
study is reasonable because of the potential enhancements in metabolic and immune system
functioning with improved nutritional status.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
Completed |
NCT01490359 -
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
|
N/A | |
Completed |
NCT03143205 -
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
|
N/A | |
Completed |
NCT02738138 -
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
|
Phase 3 | |
Completed |
NCT01791465 -
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
|
Phase 4 | |
Completed |
NCT01869634 -
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
|
Phase 4 | |
Completed |
NCT01662336 -
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
|
N/A | |
Completed |
NCT01383005 -
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
|
N/A | |
Completed |
NCT01328158 -
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
|
N/A | |
Completed |
NCT00711009 -
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
|
Phase 3 | |
Completed |
NCT02817451 -
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
|
Phase 3 | |
Completed |
NCT03284645 -
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
|
||
Terminated |
NCT01737359 -
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
|
Phase 2 | |
Active, not recruiting |
NCT05141422 -
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
|
Phase 1 | |
Completed |
NCT01939197 -
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
|
Phase 2/Phase 3 | |
Completed |
NCT01447680 -
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
|
N/A | |
Not yet recruiting |
NCT05769413 -
Awareness of Osteoporosis in HIV Patients
|
||
Withdrawn |
NCT01738555 -
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
|
Phase 2 |